重大事件
外國發行人報告
6-K
2026-06-23
argenx 舉辦自體免疫肌炎研發網絡研討會，聚焦FcRn抑制劑進展
AI 繁中摘要
6-K 申報：argenx 舉行自體免疫肌炎研發網絡研討會 📢
荷蘭阿姆斯特丹 – argenx (Euronext & Nasdaq: ARGX) 於2026年6月23日公佈，將於美東時間下午2時（歐洲中部時間同日早上7時）舉行題為「R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis」的網絡研討會。公司管理層及科學領導團隊聯同三位外部權威專家發表見解：哈佛醫學院的Avery LaChance醫生（皮膚科副教授）、西北大學范伯格醫學院的Arjun Seth醫生（神經肌肉疾病助理教授）以及匹茲堡大學的Rohit Aggarwal醫生（醫學教授兼UPMC肌炎中心聯席主任）。
研討會重點探討FcRn抑制劑在自體免疫肌炎領域的研發進展，反映argenx在FcRn靶向治療的領先地位。直播及重播（為期約一年）可於公司網站投資者專區觀看，相關簡報材料同步上載至Events & Presentations頁面。
argenx為全球免疫學公司，致力為嚴重自體免疫疾病患者開發新型抗體藥物，其首個獲批的FcRn阻斷劑已上市，並正評估其於多種適應症的潛力。是次活動有助投資者了解公司在肌炎臨床開發的最新佈局，短期內或影響市場對其管線價值的預期。🔬
展開英文正文
EX-99.1 2 tm2618529d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 argenx to Host Autoimmune Myositis R&D Webinar June 23, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, will host a webinar titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” today, June 23, 2026, at 2:00pm ET. argenx management and scientific leadership will be joined by external key opinion leaders: ·Avery LaChance, MD, MPH, FAAD, Associate Professor of Dermatology, Harvard Medical School; Director of Connective Tissue Disease Clinic ·Arjun Seth, MD, Assistant Professor, Neurology (Neuromuscular Disease), Northwestern University Feinberg School of Medicine ·Rohit Aggarwal, MD, MS, Professor of Medicine, University of Pittsburgh, and Co-Director of UPMC Myositis Center Webcast Information A live webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation. Additional materials, including supporting presentation slides, will be available on argenx’s Events & Presentations website today at 2:00pm ET. About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube. Contacts Media: Colin McBean [email protected] Investors: Alexandra Roy [email protected]